8-KLeadership Changes

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Feb 14, 2013)

Filed February 14, 2013For Securities:ALNY

Summary

This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) on February 14, 2013, details the company's 2013 Annual Incentive Program (the "Plan") approved by the Compensation Committee of the Board of Directors. The Plan is designed to provide annual cash bonuses to all regular employees, including executive officers, contingent upon achieving specified corporate and individual performance goals for the 2013 fiscal year. The structure of the bonus awards is based on a percentage of each employee's base salary, with executive officers' bonuses solely tied to corporate goal achievement. The size of the total bonus pool is determined by the company's performance against these corporate goals, with a modifier ranging from 0% to 115%. Critically, the Plan stipulates that no bonuses will be paid if the Corporate Performance Level falls below 50%, and payouts exceeding 100% of the target are contingent on achieving specific clinical development milestones. The final determination of bonus awards and their payment are expected in January 2014.

Key Highlights

  • 1Alnylam Pharmaceuticals established its 2013 Annual Incentive Program, outlining a cash bonus structure for employees.
  • 2Executive officers' bonuses are exclusively tied to the achievement of company-wide corporate goals.
  • 3All other employees' bonuses will be based on both corporate performance and individual objectives.
  • 4Target bonus awards are set as a percentage of base salary, with higher percentages for senior roles (e.g., CEO at 60%, President/COO at 50%).
  • 5The total bonus pool is influenced by a Corporate Performance Level, ranging from 0% to 115% of aggregated target awards.
  • 6Exceeding 100% of the target bonus pool is conditional on meeting specific clinical development goals.
  • 7A minimum Corporate Performance Level of 50% is required for any bonus payments to be distributed.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose the establishment and key terms of Alnylam Pharmaceuticals' 2013 Annual Incentive Program, which outlines the framework for awarding annual cash bonuses to its employees based on performance.

Bonuses for executive officers are solely based on the achievement of pre-defined corporate goals for 2013. For all other employees, bonuses will be determined by a combination of corporate performance and their individual performance against specific objectives.

Bonuses are contingent upon achieving specified corporate and individual goals. A critical condition is that if the company's overall performance against corporate goals falls below a 50% threshold, no bonuses will be paid under the plan. Payouts exceeding the target level (i.e., above 100%) are specifically linked to the achievement of specified clinical development goals.

The company plans to evaluate performance, establish the bonus pool, and determine the award amounts in December 2013. The actual bonus payments are expected to be made in January 2014.